Results 101 to 110 of about 20,527 (318)

Severe Skin Necrosis and Crusting Following Disseminated Herpes in a Kidney Transplant Patient: A Rare and Alarming Case

The Kaohsiung Journal of Medical Sciences, EarlyView.
Chung‐Ting Cheng, Lee‐Moay Lim, Hung‐Tien Kuo, Yi‐Wen Chiu   +3 more
wiley   +1 more source

Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities

Allergy, EarlyView.
ABSTRACT Over the past 70 years, oral corticosteroids (OCS) have played an important role in the management of acute and chronic asthma; however, their use is associated with an increased incidence of adverse events, chronic diseases such as osteoporosis and diabetes, and mortality, as well as increased healthcare resource utilization and costs ...
G. Walter Canonica, Celeste Porsbjerg, David B. Price, Michael E. Wechsler, Liam G. Heaney, Nicola A. Hanania, Rebecca Gall, Nami Pandit‐Abid, Juby A. Jacob‐Nara, Harry J. Sacks   +9 more
wiley   +1 more source

Re‐engagement, quality of life, and burden of treatment in adults on dupilumab for severe atopic dermatitis—A mixed methods study

Skin Health and Disease
Background Targeted biologic therapies have revolutionised the treatment of severe atopic dermatitis (AD). Objectives To assess effects of dupilumab on patient re‐engagement, quality of life (QOL), and burden of treatment (BOT) in severe AD.
Emma Porter, Cathal O’Connor, Michelle Murphy   +2 more
doaj   +1 more source

Rosacea associated with dupilumab therapy

Journal of Dermatological Treatment, 2019
Background: Dupilumab is used for treatment of atopic dermatitis through blockade of IL-4 and IL-13 signaling of the Th2 pathway. Recent case reports have described alopecia, psoriasis, persistent facial dermatitis, and recall dermatitis at patch test sites after the initiation of dupilumab therapy.Case report: We describe the case of a 67-year-old ...
Haley D. Heibel, Aleksi J. Hendricks, James P. Foshee, Vivian Y. Shi   +3 more
openaire   +2 more sources

Tumors in the setting of dupilumab use: A review of the literature

World Allergy Organization Journal
Dupilumab is the first monoclonal antibody approved for treating moderate-to-severe atopic dermatitis (AD) and has significantly improved the quality of life of AD patients.
Shumeng Guo, Liangchun Wang, MD, PhD, Dingfang Bu, MD, PhD, Fengjie Liu, MD, PhD   +3 more
doaj  

Anti‐KIT Barzolvolimab for Chronic Spontaneous Urticaria

Allergy, EarlyView.
We compared the efficacy and safety of four doses of barzolvolimab compared to placebo in reducing symptoms of chronic spontaneous urticaria in a randomized, controlled trial. Across barzolvolimab doses, rapid symptom reduction within 1 week was observed and sustained during 12 weeks.
Marcus Maurer, Martin Metz, John Anderson, Neetu Talreja, Diane Young, Elizabeth Crowley, Margo Heath‐Chiozzi, Rick Ma, Elsa Paradise, Thomas Hawthorne, Diego Alvarado, Jonathan A. Bernstein   +11 more
wiley   +1 more source

High‐Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma

Allergy, EarlyView.
We profiled PBMCs in severe asthma patients at baseline and after initiating treatment with mepolizumab or dupilumab. Mepolizumab treatment increases ILC2, Th2, and Tc2 cell frequencies, skewing ILC2 towards CD117low and Th2/Tc2 cells towards a central memory phenotype.
Lorenz Wirth, Whitney Weigel, Christopher T. Stamper, Johan Kolmert, Sabrina de Souza Ferreira, Quirin Hammer, Maria Sparreman Mikus, Jakob Theorell, Lars Andersson I, Ann‐Sofie Lantz, Eva Wallén‐Nielsen, Anne Petrén, Craig E. Wheelock, Apostolos Bossios, Nikolaos Lazarinis, Andrei Malinovschi, Christer Janson, Barbro Dahlén, Thomas Hochdörfer, Christopher Andrew Tibbitt, Sven‐Erik Dahlén, Valentyna Yasinska, Jenny Mjösberg   +22 more
wiley   +1 more source

Allergen immunotherapy and dupilumab in atopic dermatitis: Clinical efficacy and disparities in immunological indicators

World Allergy Organization Journal
Objective: Allergen immunotherapy (AIT) and dupilumab have been confirmed to improve symptoms of atopic dermatitis (AD); however, the precise immune mechanisms underlying their efficacy and whether they can elicit synergistic immune effects remain not ...
Jin Liu, MM, Lin Yang, MD, PhD, Qingxiu Xu, MD, Qing Jiang, PhD, Nan Huang, MD, Wenjing Li, PhD, Yaqi Yang, MD, Dongxia Ma, MD, Le Li, MM, Yangxue Fu, PhD, Hao Chen, PhD, Rongfei Zhu, MD, PhD   +11 more
doaj  

The Neutralization of the Eosinophil Peroxidase Antibody Accelerates Eosinophilic Mucin Decomposition [PDF]

, 2023
Eosinophilic airway inflammation, complicated by bronchial asthma and eosinophilic chronic rhinosinusitis (ECRS), is difficult to treat. The disease may become refractory when eosinophilic mucin associated with eosinophil peroxidase (EPX) and ...
Asako, Mikiya, Bui, Dan Van, Chu, Hanh Hong, Iwai, Hiroshi, Kanda, Akira, Kobayashi, Yoshiki, Mitani, Akitoshi, Nguyen, Linh Manh, Suzuki, Kensuke, Yun, Yasutaka   +9 more
core   +1 more source

Safety And Efficacy Of Dupilumab In Adult Patients With A History Of Eczema Herpeticum [PDF]

, 2018
Jette Hooper, Brian E. Weeks, David H. Dreyfus   +2 more
openalex   +1 more source